Caliway Biopharmaceuticals Co Ltd (6919) Stock Price & News

6919:TPE

Caliway Biopharmaceuticals Co Ltd

NT$60.60

-3.96%

(-2.50) 1D

Nov 4, 1:30:38 PM GMT+8 · TWD

All symbols

	Symbol	Price	Change	% Change

Next call in 4 days

Sun, Nov 8, 11:00 PM

Fiscal period

Q3 2026

- / -NT$0.20

Revenue / Est. (TWD)

- / 8.00M

Fiscal Q3 2026 earnings call

Waiting for the earnings call

At a glance: upcoming earnings

Insights from the latest news and reports

Previous reportsAll values in TWD

Loading Previous Earnings...

All values in TWD	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	13.42M	12.41M	2.00K	3.57M
Cost of goods sold	4.09M	3.40M	1.00K	1.24M
Cost of revenue	4.09M	3.40M	1.00K	1.24M
Research and development expenses	244.51M	112.62M	212.41M	210.66M
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	-33.70M	17.06M	33.42M	54.75M
Operating expense	210.81M	129.69M	245.83M	265.41M
Total operating expenses	214.89M	133.09M	245.83M	266.65M
Operating income	-201.48M	-120.68M	-245.83M	-263.08M
Other non operating income	-280.00K	9.00K	-4.00K	-2.00K
EBT including unusual items	-7.73M	80.19M	-107.75M	-222.52M
EBT excluding unusual items	-7.73M	80.19M	-107.75M	-222.52M
Income tax expense	-	-	-	-
Effective tax rate	-	-	-	-
Other operating expenses	-	-	-	-
Net income	-7.73M	80.19M	-107.75M	-222.52M
Net profit margin	-57.62%	646.17%	-5,387,700.00%	-6,239.93%
Earnings per share	-0.01	0.05	-0.07	-0.14
Interest and investment income	59.73M	85.42M	78.51M	82.27M
Interest expense	-34.00K	-22.00K	-11.00K	-329.00K
Net interest expenses	59.70M	85.40M	78.50M	81.94M
Depreciation and amortization charges	-	-	-	-
EBITDA	-195.81M	-114.79M	-239.81M	-258.15M
Gain or loss from assets sale	-	-	-	-

Finance